Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

Mesa Verde Venture Partners

Immix Biopharma (Nasdaq: IMMX)

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Read the press release here: https://loom.ly/1Pu09G0

#cancertreatment #biopharma #sciencenews

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Read the press release here: https://loom.ly/4PQGN9c

#science #biopharma #cancertreatment #multiplemyeloma #car-t

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Read the press release here: https://loom.ly/HCKoAzU

#cancertreatment #science #biopharma

Immix Biopharma is pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ 

Read more here: https://lnkd.in/emdDgvbQ

#science #cancertreatment #technology

Immix Biopharma's subsidiary Nexcella, Inc. 

Learn more about Nexcella, Inc.: https://nexcella.com/  

#biopharma #cancertreatment #science

Who founded Immix Biopharma?

Read more here: https://lnkd.in/enZ6FH3s 

#science #cancer #biopharma

Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

#healthcare #science #biopharma

Dr. Suzanne Lentzsch Joins Immix Biopharma Scientific Advisory Board

Read the press release here: https://loom.ly/spWfYjU

#sciencenews #biopharma

FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for the following: 

Read the press release here: https://loom.ly/fwrLYNQ

#fda #science #cancer

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Read the press release here: https://loom.ly/fwrLYNQ 

#science #biopharma #sciencenews

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-972.81K -	-1.15M 17.99%	-24.38M 2,024.28%	-8.23M 66.25%	-15.43M 87.44%
depreciation and amortization	1.08K -	2.32K 114.51%	2.47K 6.33%	2.13K 13.49%	5.47K 156.11%
deferred income tax			22.85M -		-2.43M -
stock based compensation			218.98K -	524.07K 139.32%	2.57M 389.57%
change in working capital	181.70K -	165.85K 8.72%	-391.04K 335.78%	195.21K 149.92%	1.65M 746.75%
accounts receivables	-36.29K -	58.49K 261.17%	97.67K 66.97%	-236.38K 342.03%	-893.40K 277.94%
inventory	36.29K -	-58.49K 261.17%	-97.67K 66.97%	236.38K 342.03%
accounts payables	122.95K -	-3.83K 103.11%	-106.06K 2,669.22%	1.13M 1,167.06%	2.43M 115.11%
other working capital	58.74K -	169.68K 188.85%	-284.97K 267.95%	-936.53K 228.64%	111.84K 111.94%
other non cash items		575K -	118.16K 79.45%	100K 15.37%	2.26M 2,164.99%
net cash provided by operating activities	-790.03K -	-404.69K 48.77%	-1.59M 292.72%	-7.41M 366.13%	-11.37M 53.50%
investments in property plant and equipment	-7.31K -		-802 -		-52.09K -
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites	-7.31K -		-802 -		-52.09K -
debt repayment			-200K -	-50K 75%
common stock issued			18.65M -	2.91M 84.38%	15.70M 438.76%
common stock repurchased				-99.96K -
dividends paid
other financing activites	1.05M -		400K -	468.28K 17.07%	-234.62K 150.10%
net cash used provided by financing activities	1.05M -		18.85M -	3.23M 82.85%	15.46M 378.44%
effect of forex changes on cash	19.03K -	61.77K 224.62%	-5.43K 108.80%	-31.52K 480.23%	33.09K 204.97%
net change in cash	271.69K -	-342.93K 226.22%	17.25M 5,131.20%	-4.21M 124.39%	4.07M 196.80%
cash at beginning of period	462.33K -	734.01K 58.77%	391.09K 46.72%	17.64M 4,411.66%	13.44M 23.85%
cash at end of period	734.01K -	391.09K 46.72%	17.64M 4,411.66%	13.44M 23.85%	17.51M 30.31%
operating cash flow	-790.03K -	-404.69K 48.77%	-1.59M 292.72%	-7.41M 366.13%	-11.37M 53.50%
capital expenditure	-7.31K -		-802 -		-52.09K -
free cash flow	-797.34K -	-404.69K 49.24%	-1.59M 292.92%	-7.41M 365.90%	-11.42M 54.20%

COM:IMMIXBIO

Immix Biopharma, Inc.

Last Close

1.68

22/11 21:00

Market Cap

53.89M

Beta: -

Volume Today

249.22K

Avg: -

Preview